2604215-74-7
2604215-74-7
Chemical Structure
Biological Activity: AZD8233 is an orally active antisense oligonucleotide targeting PCSK9 mRNA. AZD8233 highly specifically reduces PCSK9 mRNA. AZD8233 lowers LDL cholesterol. AZD8233 can be used in research on dyslipidemia[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AZD8233 | AZD8233 is an orally active antisense oligonucleotide targeting PCSK9 mRNA. AZD8233 highly specifically reduces PCSK9 mRNA. AZD8233 lowers LDL cholesterol. AZD8233 can be used in research on dyslipidemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gennemark P, et al. An oral antisense oligonucleotide for PCSK9 inhibition. Science translational medicine. 2021 May 12;13(593):eabe9117.
- [2]. Totary-Jain H, et al. Novel anti-atherosclerotic mRNA-based therapy. Atherosclerosis. 2022 Aug 1;355:27.
- [3]. Wada F, et al. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides. Molecular therapy. Nucleic acids. 2021 Dec 03;26:957-969.
- [4]. Chen S, et al. ClinASO: An open-source platform for rapid drug discovery of gapmer antisense oligonucleotides. Molecular therapy. Nucleic acids. 2026 Jun 16;37(2):102933.
- [5]. Kingwell K. Pushing the envelope with PCSK9. Nat. Rev. Drug Discov. 2021 Jul 1;20:506.
- [6]. Burnett JR, et al. MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment. Expert Opin Investig Drugs. 2023 Jul-Dec;32(10):873-878.
